A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.5B | 2.5B | 2.1B | 1.9B | 1.5B | 1.1B |
| Net Income | 451M | 451M | 404M | 283M | 245M | 181M |
| EPS | $15.28 | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 |
| Free Cash Flow | 682M | 682M | 572M | 397M | 351M | 235M |
| ROIC | 450.0% | 450.0% | 122.7% | 60.6% | 43.6% | 30.7% |
| Gross Margin | 30.1% | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% |
| Debt/Equity | 0.30 | 0.30 | 0.18 | 0.29 | 0.67 | 0.15 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 535M | 535M | 447M | 337M | 279M | 199M |
| Operating Margin | 21.1% | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% |
| ROE | 98.3% | 70.2% | 58.4% | 59.8% | 36.6% | 20.6% |
| Shares Outstanding | 30M | 30M | 32M | 32M | 34M | 38M |
Medpace Holdings, Inc. passes 7 of 9 quality checks, indicating strong fundamentals.
Medpace Holdings, Inc. trades at 34.0x trailing earnings, compared to its 15-year median P/E of 35.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 21.6x vs a median of 19.5x. The company's 5-year average ROIC is 64.4% with a gross margin of 29.5%. Total shareholder yield (buybacks) is 6.0%. At current prices, the estimated annualized return to fair value is +30.5%.
Medpace Holdings, Inc. (MEDP) has a current P/E ratio of 34.0, compared to its historical median P/E of 35.5. The stock is currently considered Fair based on its historical valuation range.
Medpace Holdings, Inc. (MEDP) has a 5-year average return on invested capital (ROIC) of 64.4%. This indicates strong capital allocation and a potential competitive advantage.
Medpace Holdings, Inc. (MEDP) has a market capitalization of $15.4B. It is classified as a large-cap stock.
Medpace Holdings, Inc. (MEDP) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 5.98%.
Based on historical P/E analysis, Medpace Holdings, Inc. (MEDP) appears fair. The current P/E of 34.0 is 4% below its historical median of 35.5. The estimated fair value CAGR (P/E method) is 34.8%.
Medpace Holdings, Inc. (MEDP) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
Medpace Holdings, Inc. (MEDP) reported annual revenue of $2.5 billion in its most recent fiscal year, based on SEC EDGAR filings.
Medpace Holdings, Inc. (MEDP) has a net profit margin of 17.8%. This is a healthy margin.
Medpace Holdings, Inc. (MEDP) generated $682 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Medpace Holdings, Inc. (MEDP) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
Medpace Holdings, Inc. (MEDP) reported earnings per share (EPS) of $15.28 in its most recent fiscal year.
Medpace Holdings, Inc. (MEDP) has a return on equity (ROE) of 70.2%. This indicates the company generates strong returns for shareholders.
Medpace Holdings, Inc. (MEDP) has a 5-year average gross margin of 29.5%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 11 years of financial data for Medpace Holdings, Inc. (MEDP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Medpace Holdings, Inc. (MEDP) has a book value per share of $15.55, based on its most recent annual SEC filing.